Document 0701
 DOCN  M94A0701
 TI    Acetylation phenotype and hypersensitivity (HS) to
       trimethoprim-sulphamethoxazole (TMP-SMX) in HIV-infected patients.
 DT    9412
 AU    Carr A; Gross A; Cooper DA; Centre for Immunology, St. Vincent's
       Hospital.
 SO    Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:31 (abstract no.
       TC11). Unique Identifier : AIDSLINE ASHM5/94348954
 AB    AIMS: HS to TMP-SMX is more common in patients with HIV infection. In
       those without HIV infection, HS is more common in those with a slow
       acetylator phenotype. A study was conducted to determine if the slow
       acetylation phenotype is associated with an increased risk of HS to
       TMP-SMX in patients with HIV. METHODS: Acetylation phenotype was
       determined by measuring the ratio of two urinary caffeine metabolites,
       5-acetylamino-6-amino-3-methyl uracil and 1-methyl xanthine after
       ingestion of a single 200 mg dose of caffeine. RESULTS: Of the 28
       subjects, 20 (71%) expressed a slow acetylation phenotype and 8 (29%) a
       fast phenotype. Of the 16 subjects with prior HS, 15 (94%) had a slow
       acetylation phenotype, versus 5 (42%) of 12 subjects with a fast
       phenotype (P < 0.01). CONCLUSIONS: HIV-infected subjects have an
       increased prevalence of the slow acetylation phenotype. A slow
       acetylation phenotype correlates with a history of HS to TMP-SMX.
 DE    Acetylation  Caffeine/DIAGNOSTIC USE/PHARMACOKINETICS  Drug
       Hypersensitivity/*GENETICS  Human  HIV Infections/*DRUG THERAPY/GENETICS
       *Phenotype  Risk Factors  Trimethoprim-Sulfamethoxazole
       Combination/*ADVERSE EFFECTS/  PHARMACOKINETICS/THERAPEUTIC USE  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).